Deepening the reform of the drug review and approval system and continuing to improve the research and innovation environmentKONG Fan-pu2393-2397
Research on administration mode of enterprise legal person designated by overseas drug marketing authorization holdersJIANG Xiao-meng, WU Yi-fan, YANG Yue, SUN Li-hua2398-2403
Reference value of PDUFA Act to improvement of the review ability of drug regulatory agenciesWU Yi-fan, ZHANG Wei, YU Wei, YANG Yue, LIU Zuo-ren2404-2412
Regulatory considerations for synergistic protection of patents and data exclusivity for innovative therapeutic biologicsDU Xin, LUO Xing-xian, YANG Yue, SUN Li-hua2413-2421
Research on definition of rare diseases in China and estimation of cumulative point prevalence based on OrphadataLI Zhuang-qi, YANG Pu, YANG Yue2422-2428
The consideration behind America's Advancing process of OTC marketing pathwayTANG Tian-yu, WU Yi-fan, YANG Pu, LI Jing-ran, YANG Yue, XING Hua2429-2436
Regulatory considerations for clinical evaluation of HPV vaccines by using immunological surrogate endpointHE Xiang-chuan, YANG Jing-shu, LIU Jing-wen, YUAN Yuan, HUAN Shi-tong, DU Heng, YANG Yue2437-2443
Preliminary study on China's innovative biological product registration classificationGUO Qi-xiang, YANG Jing-shu, YANG Yue2444-2451
Suggestions on establishing a regulatory coordination path for export only vaccines in ChinaYANG Yue, WU Yi-fan, HUAN Shi-tong, DU Heng, GAO Guang, YUAN Yuan2452-2457
Comparison of the selection and management of reference medicinal products of chemical generic drugs in China and AmericaYOU Zheng-kun, SUN Chun-meng, LIU Yi-lin, GUO Zhi-xin, TU Jia-sheng2458-2464